Catalyst Calendar - February 10, 2026 (Morning)

 ## Major Catalysts Mentioned **Electronic Arts (EA)** - Date: TBD - Why it matters: JPMorgan has initiated a $1.5 billion bond buyback for Electronic Arts, which could signal confidence in the company’s financial health and future growth prospects. - Stocks affected: **$EA** **AstraZeneca (AZN)** - Date: TBD - Why it matters: AstraZeneca's Q4 2025 earnings report shows an 8% revenue growth, indicating strong performance in its drug pipeline, particularly in oncology and cardiovascular treatments. - Stocks affected: **$AZN** **Bonk Inc.** - Date: TBD - Why it matters: Bonk Inc. has reported a net revenue of $2.46 million for January, highlighting interest in its BONK.fun platform, potentially positioning it for future growth. - Stocks affected: **$BONK** **Marriott International (MAR)** - Date: TBD - Why it matters: Marriott is experiencing strong growth in credit card fees, particularly in markets like Japan and the UAE, which could bolster its revenue despite challenges in business travel. - Stocks affected: **$MAR** **Bunker Hill Mining (BHMG)** - Date: TBD - Why it matters: Bunker Hill Mining has announced a C$30 million brokered LIFE offering, which could provide necessary capital for operations and future projects. - Stocks affected: **$BHMG** ## Earnings on Deck - **$AZN** - Reports: TBD - Key watch: Revenue growth in key therapeutic areas. - **$MAR** - Reports: TBD - Key watch: Credit card fee growth and overall revenue performance. ## Economic Events - **U.S. Job Additions** - January - Expected impact: Continued job growth is crucial for economic stability and consumer spending. ## What's NOT Dated But Worth Tracking - **Retail Sales Trends** - Watch for: Ongoing impacts of tariffs and consumer behavior changes; recent reports indicate flat retail sales which could signal economic slowdown. - **AI Developments in Corporate Spending** - Watch for: Companies adapting budgets to integrate AI technologies amid evolving market demands. ## Highest Conviction Catalyst - What: **AstraZeneca's Q4 2025 Earnings Report** - When: TBD - Why it matters: With an 8% revenue increase, this report could significantly impact investor sentiment and stock performance, particularly as it reflects strong demand in critical therapeutic areas. The company's potential growth trajectory and ability to navigate cost pressures will be closely monitored by analysts and investors alike. - Trade idea: Consider bullish positions in **$AZN** if guidance remains positive, especially focusing on oncology and cardiovascular drugs.